BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18651826)

  • 21. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
    Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
    J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
    Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
    Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
    Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
    Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.
    Giannopoulos G; Pavlakis K; Parasi A; Kavatzas N; Tiniakos D; Karakosta A; Tzanakis N; Peros G
    Anticancer Res; 2008; 28(3B):1875-81. PubMed ID: 18630474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
    Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
    He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
    Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
    Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
    Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
    O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
    Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced tissue inhibitor of metalloproteinase-2 expression is associated with advanced medullary thyroid carcinoma.
    Wajner SM; Capp C; Brasil BA; Meurer L; Maia AL
    Oncol Lett; 2014 Mar; 7(3):731-737. PubMed ID: 24527080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
    Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
    Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma.
    Mashhadiabbas F; Mahjour F; Mahjour SB; Fereidooni F; Hosseini FS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Aug; 114(2):240-50. PubMed ID: 22769410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas.
    Ondruschka C; Buhtz P; Motsch C; Freigang B; Schneider-Stock R; Roessner A; Boltze C
    Pathol Res Pract; 2002; 198(8):509-15. PubMed ID: 12389993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival.
    de Vries LH; Lodewijk L; Willems SM; Dreijerink KMA; de Keizer B; van Diest PJ; Schepers A; Bonenkamp HJ; van Engen-van Grunsven IACH; Kruijff S; van Hemel BM; Links TP; Nieveen van Dijkum EJM; van Eeden S; Valk GD; Borel Rinkes IHM; Vriens MR
    Endocrine; 2018 Dec; 62(3):639-647. PubMed ID: 30128959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in microcystic meningiomas.
    Paek SH; Kim DG; Park CK; Phi JH; Kim YY; Im SY; Kim JE; Park SH; Jung HW
    Oncol Rep; 2006 Jul; 16(1):49-56. PubMed ID: 16786122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of CD147 gene silencing on protein expression of ANXA2, MMP-2 and TIMP-2 by thyroid medullary carcinoma TT cells and biologic characteristics].
    Li J; Li D; Zhang L; Huang P; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):103-8. PubMed ID: 24742570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
    Bozkurt C; Ertem U; Oksal A; Sahin G; YĆ¼ksek N; Birgen D
    Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated expression levels of matrix metalloproteinase-9 in placental villi and tissue inhibitor of metalloproteinase-2 in decidua are associated with prolonged bleeding after mifepristone-misoprostol medical abortion.
    Zhuang Y; Qian Z; Huang L
    Fertil Steril; 2014 Jan; 101(1):166-171.e2. PubMed ID: 24210229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.